Agonist Medications for the Treatment of Cocaine Use Disorder
about
Use of Preclinical Drug vs. Food Choice Procedures to Evaluate Candidate Medications for Cocaine AddictionPreclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure.Effects of the dopamine/norepinephrine releaser phenmetrazine on cocaine self-administration and cocaine-primed reinstatement in ratsPilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trialEffects of L-methamphetamine treatment on cocaine- and food-maintained behavior in rhesus monkeys.Attenuation of cocaine self-administration by chronic oral phendimetrazine in rhesus monkeysThe effects of oral d-amphetamine on impulsivity in smoked and intranasal cocaine users.Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research.Development of a translational model to screen medications for cocaine use disorder II: Choice between intravenous cocaine and money in humans.How contexts promote and prevent relapse to drug seeking.Insights from Preclinical Choice Models on Treating Drug Addiction.Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques.Effects of 21-day d-amphetamine and risperidone treatment on cocaine vs food choice and extended-access cocaine intake in male rhesus monkeys.The individual and combined effects of phenmetrazine and mgluR2/3 agonist LY379268 on the motivation to self-administer cocaine.Development of a translational model to screen medications for cocaine use disorder I: Choice between cocaine and food in rhesus monkeys.Circumspectives: The Replacements.Role of d-amphetamine and d-methamphetamine as active metabolites of benzphetamine: Evidence from drug discrimination and pharmacokinetic studies in male rhesus monkeys.Effects of Acute and Chronic Treatments with Dopamine D2 and D3 Receptor Ligands on Cocaine versus Food Choice in Rats.Maintenance on naltrexone+amphetamine decreases cocaine-vs.-food choice in male rhesus monkeys.Increased Depression and Anxiety Symptoms are Associated with More Breakdowns in Cognitive Control to Cocaine Cues in Veterans with Cocaine Use Disorder.Overview of Monoamine Transporters.Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation.The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders.Selective inhibition of M5 muscarinic acetylcholine receptors attenuates cocaine self-administration in rats.Regional and source-based patterns of [11C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D2 and D3 receptor availability in cocaine-use disorder.Formulation and evaluation of 4-benzylpiperidine drug-in-adhesive matrix type transdermal patch
P2860
Q35636912-F65B9F65-43ED-49DB-A386-B8A0638AB1E5Q35691213-0A0A8690-F852-4E2E-B492-D16DE8E9DD5AQ35738069-B9C60BA4-B6EF-4C73-A981-5EE851EF0B6DQ35875805-95C12AAE-E643-4DE0-B401-CA879105C6C3Q36600161-713782D4-4CFD-4DFF-95C1-4204F4A95A1AQ36818345-754D4476-8B29-4DE2-879C-BE1B4A9E6A76Q36936174-3D0964B0-7550-4113-8C00-AF28AED256F2Q37062538-5627C662-C2D0-48D3-9B35-A54251A97826Q38857284-26022625-70E3-486D-8B8B-ED83945B7AF1Q38950401-C149FB97-3DE7-45DE-A6F6-4FE5C81636D7Q39028819-6C61BC17-EEAD-4895-A354-00ECF6CE8448Q39327496-682D2B1F-C7BE-4946-8C74-7471CF182BB4Q39403292-BD05B87E-6D50-4B28-BF5F-7118F4D9D66EQ39618347-08529F5E-646C-422D-A4CF-B12CCEC7FB50Q42426966-2852B2B1-8A68-468B-8117-345D00A97B20Q42870333-020CC1EF-C8D1-4EFB-ABCD-079B3EA09ED3Q45056291-2CCCFC2C-2EBB-41CF-8E07-8820928E4CADQ45058435-7E54EEFA-3ED8-41FE-ABDF-AA46EF929BC8Q45070304-37241B36-55B9-4F9A-A4F1-D4D647E8ED30Q45325808-CF8FB243-82F3-4F7D-940E-C6EEB0E307CDQ47271566-E49C4AEF-BB3A-4E58-B5DC-2350281F8D1AQ47305133-2F1EE31F-2FD3-400D-BFAD-488B47067FF3Q47677518-CCD31A94-B9AA-4CF9-9935-61B75FFE8D8DQ48167663-DA583F17-BFB9-487E-AD37-24DCD0F435C3Q48346301-1D336CA9-0CB0-4D5E-BF64-F030DD201A37Q57785830-84E6A044-02F5-4669-9542-009958E936FD
P2860
Agonist Medications for the Treatment of Cocaine Use Disorder
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Agonist Medications for the Treatment of Cocaine Use Disorder
@ast
Agonist Medications for the Treatment of Cocaine Use Disorder
@en
Agonist Medications for the Treatment of Cocaine Use Disorder
@nl
type
label
Agonist Medications for the Treatment of Cocaine Use Disorder
@ast
Agonist Medications for the Treatment of Cocaine Use Disorder
@en
Agonist Medications for the Treatment of Cocaine Use Disorder
@nl
prefLabel
Agonist Medications for the Treatment of Cocaine Use Disorder
@ast
Agonist Medications for the Treatment of Cocaine Use Disorder
@en
Agonist Medications for the Treatment of Cocaine Use Disorder
@nl
P2860
P356
P1476
Agonist Medications for the Treatment of Cocaine Use Disorder
@en
P2093
Jack Henningfield
S Stevens Negus
P2860
P2888
P304
P356
10.1038/NPP.2014.322
P407
P577
2015-07-01T00:00:00Z
P5875
P6179
1051994022